<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830699</url>
  </required_header>
  <id_info>
    <org_study_id>FKE20120016H</org_study_id>
    <nct_id>NCT01830699</nct_id>
  </id_info>
  <brief_title>Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis</brief_title>
  <official_title>Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keesler Air Force Base Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keesler Air Force Base Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date no trials have been performed looking at whether or not intra-bursal injection of an
      IL-1 antagonist provides pain relief similar to that of a corticosteroid injection. The
      subcutaneous injection of anakinra, an IL-1 receptor antagonist, in patients with shoulder
      pain due to rotator cuff tendonitis and subacromial bursitis was efficacious in relieving
      pain but this information was presented as a case series in a letter to the editor format, so
      the validity of these results would require additional testing [Omoigui S, et al. 2004].
      Based mainly on the data from the intra-articular administration of anakinra, there have not
      been any adverse trends in outcomes or safety to suggest that intra-bursal injection of
      rilonacept will carry an increase risk of adverse events. The purpose of this trial is to
      compare the improvement in pain and function of patients with clinical symptoms and signs of
      subacromial bursitis of rilonacept vs. corticosteroid injection (standard of care).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Subacromial bursitis is an inflammatory condition which is typically triggered by
      altered rotator cuff mechanics. One of the mainstays of therapy is corticosteroid injection.
      Given the inflammatory nature of subacromial bursitis coupled with prominence of
      interleukin-1 (IL-1) beta on histopathologic assessment of resected subacromial bursa,
      targeted anti-IL-1 therapy would be an attractive alternative to corticosteroid injection.

      Hypothesis: One intra-bursal injection of the IL-1 trap rilonacept (Arcalyst ®), currently
      FDA approved for the treatment of cryopyrin associated periodic syndrome (CAPS), is
      non-inferior to intra-bursal corticosteroid injection at 4 weeks post-procedure.

      Methods: This study is a prospective trial lasting a total of 4 weeks. Patients with typical
      symptoms and signs of subacromial bursitis are randomized to either corticosteroid injection
      prepared in the usual fashion in clinic vs. injection of rilonacept. Prior to injection of
      either medication patients will complete a QuickDASH Questionnaire and provide a verbal pain
      score from 0 to 10. The Quick DASH Questionnaire and verbal pain score are then completed
      within 2 duty days of injection, 2 weeks after injection, and 4 weeks after injection by
      phone.

      Primary Outcome: Primary outcome is improvement in QuickDASH. Secondary outcomes are
      improvement in the verbal pain score and monitoring for infection or other complications from
      rilonacept administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Shoulder Function</measure>
    <time_frame>4 weeks</time_frame>
    <description>The QuickDASH will be used as the primary outcome to assess improvement in pain and function of patients with clinical symptoms and signs of subacromial bursitis randomized to either rilonacept vs. corticosteroid injection. The QuickDASH is an 11 question form, a short version of the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH). It ranges from 0 (no symptoms/full function) to 100 (maximal symptoms/no function). No units are specified. Cutoff scores: &lt; 15 = no problem, 16 - 40 = problem, but working, &gt; 40 = unable to work. US population mean +/- SD is 10.1 +/- 14.7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Pain</measure>
    <time_frame>4 weeks</time_frame>
    <description>Secondary outcomes are improvement in pain (as assessed by patient self report, range between 0 and 10, with 0 as no pain and 10 described as the worst pain in their life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>4 weeks</time_frame>
    <description>Any adverse event reported by the study participant during the four time points studied in the trial in either arm will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Subacromial Bursitis</condition>
  <arm_group>
    <arm_group_label>Rilonacept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>80 mg (2 cc of 40 mg/mL) Kenalog intra-bursal once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilonacept</intervention_name>
    <description>160 mg intra-bursal once</description>
    <arm_group_label>Rilonacept</arm_group_label>
    <other_name>Arcalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>2 cc (40 mg/mL) triamcinolone intra-bursal once</description>
    <arm_group_label>Corticosteroid</arm_group_label>
    <other_name>Triamcinolone (Kenalog)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age or older and at a minimum have a recent history (more than 3
             days worth) of shoulder pain with moderate to severe tenderness to palpation over the
             subacromial bursa.

        Exclusion Criteria:

          -  Allergies to lidocaine, marcaine, or kenalog.

          -  Allergies to rilonacept

          -  Flare of active inflammatory arthritis (such as a flare of Rheumatoid Arthritis)

          -  Gout or Pseudogout attack of the shoulder with subacromial tenderness

          -  Active infection

          -  Actively receiving chemotherapy, radiation therapy, or anticipating surgery for
             neoplasia

          -  Active myocardial infarction

          -  Clinical and/or radiographic evidence of a fracture (clavicular, humeral, or other).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew B Carroll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keesler Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keesler Medical Center</name>
      <address>
        <city>Keesler AFB</city>
        <state>Mississippi</state>
        <zip>39534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2013</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <results_first_submitted>May 10, 2014</results_first_submitted>
  <results_first_submitted_qc>July 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2014</results_first_posted>
  <last_update_submitted>July 13, 2014</last_update_submitted>
  <last_update_submitted_qc>July 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rilonacept</keyword>
  <keyword>Subacromial Bursitis treatment</keyword>
  <keyword>Corticosteroid Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bursitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subject recruitment was from March 2013 to December 2013. Subjects were recruited from the Internal Medicine (IM) or IM Subspecialties Clinic at a single academic community-size hospital.</recruitment_details>
      <pre_assignment_details>Please refer to inclusion and exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Triamcinolone (Kenalog)</title>
          <description>A mixture of lidocaine without epinephrine, bupivicaine, and 80 mg of triamcinolone acetonide will be injected in the subacromial bursa.
Corticosteroid (Triamcinolone (Kenalog) )</description>
        </group>
        <group group_id="P2">
          <title>Rilonacept</title>
          <description>160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
Rilonacept: 160 mg intra-bursal once</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Prior to starting the trial, we anticipated having to recruit 150 subjects total (75 in each arm). At our first analysis of the data, the effect size of both the rilonacept and triamcinolone were larger than expected, and a re-calculated 'n' was 29 for an alpha of 0.05 and power of 1.0000 (effect size 1.1).</population>
      <group_list>
        <group group_id="B1">
          <title>Triamcinolone (Kenalog)</title>
          <description>A mixture of lidocaine without epinephrine, bupivicaine, and 80 mg of triamcinolone acetonide will be injected in the subacromial bursa.
Corticosteroid (Triamcinolone (Kenalog) )</description>
        </group>
        <group group_id="B2">
          <title>Rilonacept</title>
          <description>160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
Rilonacept: 160 mg intra-bursal once</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" spread="13.7"/>
                    <measurement group_id="B2" value="64.5" spread="12.1"/>
                    <measurement group_id="B3" value="65.3" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Site of subacromial injection</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Right Bursa injected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Bursa injected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Shoulder Function</title>
        <description>The QuickDASH will be used as the primary outcome to assess improvement in pain and function of patients with clinical symptoms and signs of subacromial bursitis randomized to either rilonacept vs. corticosteroid injection. The QuickDASH is an 11 question form, a short version of the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH). It ranges from 0 (no symptoms/full function) to 100 (maximal symptoms/no function). No units are specified. Cutoff scores: &lt; 15 = no problem, 16 - 40 = problem, but working, &gt; 40 = unable to work. US population mean +/- SD is 10.1 +/- 14.7.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triamcinolone (Kenalog)</title>
            <description>A mixture of lidocaine without epinephrine, bupivicaine, and 80 mg of triamcinolone acetonide will be injected in the subacromial bursa.
Corticosteroid (Triamcinolone (Kenalog) )</description>
          </group>
          <group group_id="O2">
            <title>Rilonacept</title>
            <description>160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
Rilonacept: 160 mg intra-bursal once</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Shoulder Function</title>
          <description>The QuickDASH will be used as the primary outcome to assess improvement in pain and function of patients with clinical symptoms and signs of subacromial bursitis randomized to either rilonacept vs. corticosteroid injection. The QuickDASH is an 11 question form, a short version of the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH). It ranges from 0 (no symptoms/full function) to 100 (maximal symptoms/no function). No units are specified. Cutoff scores: &lt; 15 = no problem, 16 - 40 = problem, but working, &gt; 40 = unable to work. US population mean +/- SD is 10.1 +/- 14.7.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.92" spread="15.40"/>
                    <measurement group_id="O2" value="38.52" spread="25.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Setting α=0.05 and β=0.8, with effect size of 0.17 anticipated total n = 138 to be recruited (requested recruitment of 150 to account for possible drop-outs)
1st data analysis (n = 33), effect size calculated at 1.1 with new n = 29 with α=0.05 and β=1.0.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For details of power calculation, see above. Using a minimal clinical importance of -9.1, the null hypothesis was a mean difference less than -9.1.</non_inferiority_desc>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-23.9</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Pain</title>
        <description>Secondary outcomes are improvement in pain (as assessed by patient self report, range between 0 and 10, with 0 as no pain and 10 described as the worst pain in their life).</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triamcinolone (Kenalog)</title>
            <description>A mixture of lidocaine without epinephrine, bupivicaine, and 80 mg of triamcinolone acetonide will be injected in the subacromial bursa.
Corticosteroid (Triamcinolone (Kenalog) )</description>
          </group>
          <group group_id="O2">
            <title>Rilonacept</title>
            <description>160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
Rilonacept: 160 mg intra-bursal once</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Pain</title>
          <description>Secondary outcomes are improvement in pain (as assessed by patient self report, range between 0 and 10, with 0 as no pain and 10 described as the worst pain in their life).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" spread="1.42"/>
                    <measurement group_id="O2" value="3.85" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Setting α=0.05 and β=0.8, with effect size of 0.17 anticipated total n = 138 to be recruited (requested recruitment of 150 to account for possible drop-outs)
1st data analysis (n = 33), effect size calculated at 1.1 with new n = 29 with α=0.05 and β=1.0.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>See details above regarding effect size, power, etc.</non_inferiority_desc>
            <p_value>0.044</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>Any adverse event reported by the study participant during the four time points studied in the trial in either arm will be recorded.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triamcinolone (Kenalog)</title>
            <description>A mixture of lidocaine without epinephrine, bupivicaine, and 80 mg of triamcinolone acetonide will be injected in the subacromial bursa.
Corticosteroid (Triamcinolone (Kenalog) )</description>
          </group>
          <group group_id="O2">
            <title>Rilonacept</title>
            <description>160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
Rilonacept: 160 mg intra-bursal once</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>Any adverse event reported by the study participant during the four time points studied in the trial in either arm will be recorded.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Triamcinolone (Kenalog)</title>
          <description>A mixture of lidocaine without epinephrine, bupivicaine, and 80 mg of triamcinolone acetonide will be injected in the subacromial bursa.
Corticosteroid (Triamcinolone (Kenalog) )</description>
        </group>
        <group group_id="E2">
          <title>Rilonacept</title>
          <description>160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
Rilonacept: 160 mg intra-bursal once</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>One subject in the rilonacept arm was hospitalized for diarrhea, heme-occult positive stool, and an INR of 3.4. One subject in the triamcinolone arm was hospitalized for shortness of breath for which an etiology was never identified.</description>
                <counts group_id="E1" events="12" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="20" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Thrush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Acute Bronchitis</sub_title>
                <description>Required antibiotics</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Generalized Stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hand Tingling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew B. Carroll, MD</name_or_title>
      <organization>Keesler Medical Center</organization>
      <phone>228-376-3629</phone>
      <email>matthew.carroll.1@us.af.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

